{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:20:28Z","timestamp":1792552828793,"version":"4.5.0"},"reference-count":57,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:sec id=\"ab-ooi260007-4\">\n                    <jats:title>IMPORTANCE<\/jats:title>\n                    <jats:p>Neoadjuvant chemoimmunotherapy has high rates of pathologic response and improved prognosis among solid tumors. Its role in head and neck squamous cell carcinoma (HNSCC) remains understudied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi260007-5\">\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To summarize the efficacy associated with neoadjuvant chemoimmunotherapy regimens in HNSCC and to compare the efficacy associated with neoadjuvant chemoimmunotherapy vs immunotherapy alone in locoregionally advanced resectable HNSCC prior to definitive surgery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi260007-6\">\n                    <jats:title>DATA SOURCES<\/jats:title>\n                    <jats:p>A librarian-led systematic review was conducted using multiple electronic databases, including Medline, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Scopus, following Preferred Reporting Items for Systematic Reviews and Meta- Analyses (PRISMA) guidelines. Databases were queried from inception to October 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi260007-7\">\n                    <jats:title>STUDY SELECTION<\/jats:title>\n                    <jats:p>Inclusion criteria included prospective interventional trials that have completed accrual, with results published in English. Only trials of resectable, treatment-naive HNSCC were included. Exclusion criteria included lack of reporting on pathologic response or Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi260007-8\">\n                    <jats:title>DATA EXTRACTION AND SYNTHESIS<\/jats:title>\n                    <jats:p>Two investigators independently conducted title, abstract, and full-text reviews per PRISMA guidelines. Primary outcomes extracted were major pathologic response (MPR) and complete pathologic response (CPR) at surgery and complete response (CR) on imaging by RECIST 1.1. Secondary outcomes included 1-year overall survival (OS) and toxic effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi260007-9\">\n                    <jats:title>MAIN OUTCOMES AND MEASURES<\/jats:title>\n                    <jats:p>\n                      A meta-analysis was performed using a binary random-effects model to determine the pooled proportion of primary outcomes in the immunotherapy and chemoimmunotherapy groups. Heterogeneity was reported as\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi260007-10\">\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      A total of 751 patients (502 [77%] male; age range, 27-87 years) across 23 studies were included in the meta-analysis, including 357 patients (47%) who underwent chemoimmunotherapy, 102 patients (14%) who underwent dual-agent immunotherapy, and 292 patients (39%) who underwent single-agent immunotherapy. Pooled rates of MPR plus CPR were 66% (95% CI, 58%-73%;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.59) for chemoimmunotherapy, 18% (95% CI, 6%-29%;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090.65) for dual-agent immunotherapy, and 6% (95% CI, 3%-9%;\n                      <jats:italic toggle=\"yes\">I<\/jats:italic>\n                      <jats:sup>2<\/jats:sup>\n                      \u2009&amp;amp;lt;\u20090.01) for single-agent immunotherapy. Across all groups, 1-year OS rates ranged from 88% to 96% for single-agent immunotherapy, 88% to 96% for dual-agent immunotherapy, and 88% to 100% for chemoimmunotherapy. Grade 3 to 5 adverse events were reported in 61 of 210 patients (29%), 2 of 67 patients (3.0%), and 36 of 210 patients (17%) among the reporting studies in the single-agent immunotherapy, dual-agent immunotherapy, and chemoimmunotherapy groups, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi260007-11\">\n                    <jats:title>CONCLUSIONS AND RELEVANCE<\/jats:title>\n                    <jats:p>These findings suggest that neoadjuvant chemoimmunotherapy regimens were associated with higher pathologic and radiographic response rates compared with immunotherapy alone in locoregionally advanced HNSCC. These results call for phase 3 trials comparing these neoadjuvant regimens head to head.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoto.2026.0080","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:30:34Z","timestamp":1773329434000},"page":"490","source":"Crossref","is-referenced-by-count":10,"title":["Neoadjuvant Immunotherapy and Chemoimmunotherapy Regimens in Head and Neck Cancer"],"prefix":"10.1001","volume":"152","author":[{"given":"Hannah Q.","family":"Baratz","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecelia","family":"Hidalgo","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Price","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Van Abel","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Lester","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Routman","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binav","family":"Baral","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry E.","family":"Fuentes Bayne","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"McGarrah","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine R.","family":"Price","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda X.","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"ooi260007r1","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1002\/cncr.29251","article-title":"Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.","volume":"121","author":"Iyer","year":"2015","journal-title":"Cancer"},{"issue":"24","key":"ooi260007r2","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJM199106133242402","article-title":"Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.","volume":"324","author":"Wolf","year":"1991","journal-title":"N Engl J Med"},{"issue":"2","key":"ooi260007r3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/S1470-2045(11)70346-1","article-title":"Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.","volume":"13","author":"Bourhis","year":"2012","journal-title":"Lancet Oncol"},{"issue":"7","key":"ooi260007r4","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","article-title":"Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.","volume":"31","author":"Forastiere","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"ooi260007r5","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.ijrobp.2012.05.008","article-title":"Long-term follow-up of the RTOG 9501\/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck.","volume":"84","author":"Cooper","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"ooi260007r6","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.","volume":"357","author":"Posner","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"ooi260007r7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1001\/jamaoto.2016.3669","article-title":"Survival rates using individualized bioselection treatment methods in patients with advanced laryngeal cancer.","volume":"143","author":"Wolf","year":"2017","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"17","key":"ooi260007r8","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1056\/NEJMoa071028","article-title":"Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.","volume":"357","author":"Vermorken","year":"2007","journal-title":"N Engl J Med"},{"issue":"11","key":"ooi260007r9","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.oraloncology.2012.06.014","article-title":"Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a meta-analysis.","volume":"48","author":"Ma","year":"2012","journal-title":"Oral Oncol"},{"issue":"6","key":"ooi260007r10","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat Med"},{"issue":"18","key":"ooi260007r11","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma.","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"issue":"24","key":"ooi260007r12","doi-asserted-by":"publisher","first-page":"7474","DOI":"10.1158\/1078-0432.CCR-17-2005","article-title":"Immune activation in early-stage non-small cell lung cancer patients receiving neoadjuvant chemotherapy plus ipilimumab.","volume":"23","author":"Yi","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"ooi260007r13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","article-title":"Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial.","volume":"10","author":"Sharma","year":"2024","journal-title":"JAMA Oncol"},{"issue":"3","key":"ooi260007r14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.eururo.2023.11.008","article-title":"Spatial relationships in the tumor microenvironment demonstrate association with pathologic response to neoadjuvant chemoimmunotherapy in muscle-invasive bladder cancer.","volume":"85","author":"Beckabir","year":"2024","journal-title":"Eur Urol"},{"issue":"16","key":"ooi260007r15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.6012","article-title":"Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): exploratory efficacy analyses of the phase 3 KEYNOTE-689 study.","volume":"43","author":"Adkins","year":"2025","journal-title":"J Clin Oncol"},{"key":"ooi260007r16","doi-asserted-by":"publisher","first-page":"LBA2","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA2","article-title":"NIVOPOSTOP (GORTEC 2018-01): a phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse.","volume":"43","author":"Bourhis","year":"2025","journal-title":"J Clin Oncol"},{"key":"ooi260007r17","first-page":"217","article-title":"HELLP syndrome. 7-year experience at the National Institute of Perinatology.","volume":"63","author":"Argueta Z\u00fa\u00f1iga","year":"1995","journal-title":"Ginecol Obstet Mex"},{"issue":"21","key":"ooi260007r18","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer.","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"ooi260007r19","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"issue":"1","key":"ooi260007r20","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"ooi260007r21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"10","key":"ooi260007r22","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1158\/1078-0432.CCR-23-3249","article-title":"A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma.","volume":"30","author":"Kim","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"ooi260007r23","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1038\/s41467-024-46444-z","article-title":"Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial.","volume":"15","author":"Wu","year":"2024","journal-title":"Nat Commun"},{"key":"ooi260007r24","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.106918","article-title":"Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.","volume":"156","author":"Zhao","year":"2024","journal-title":"Oral Oncol"},{"issue":"16","key":"ooi260007r25","doi-asserted-by":"publisher","first-page":"6018","DOI":"10.1200\/JCO.2023.41.16_suppl.6018","article-title":"Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).","volume":"41","author":"Ferris","year":"2023","journal-title":"J Clin Oncol"},{"issue":"21","key":"ooi260007r26","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/cncr.34930","article-title":"A phase 2 study of neoadjuvant chemotherapy plus durvalumab in resectable locally advanced head and neck squamous cell carcinoma.","volume":"129","author":"Patel","year":"2023","journal-title":"Cancer"},{"issue":"10","key":"ooi260007r27","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/cac2.12480","article-title":"Intratumoral CD103+ CD8+ T cells predict response to neoadjuvant chemoimmunotherapy in advanced head and neck squamous cell carcinoma.","volume":"43","author":"Ren","year":"2023","journal-title":"Cancer Commun (Lond)"},{"key":"ooi260007r28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1189752","article-title":"Efficacy and safety of pembrolizumab with preoperative neoadjuvant chemotherapy in patients with resectable locally advanced head and neck squamous cell carcinomas.","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"ooi260007r29","doi-asserted-by":"publisher","first-page":"6019","DOI":"10.1200\/JCO.2023.41.16_suppl.6019","article-title":"Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab to deescalate surgery and omit adjuvant radiation in locoregionally advanced head & neck squamous cell carcinoma (HNSCC).","volume":"41","author":"Wong","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"ooi260007r30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e18072","article-title":"Neoadjuvant tislelizumab combined with chemotherapy in locally advanced oral or oropharyngeal squamous cell carcinoma: a single-arm, phase II trial.","volume":"41","author":"Wu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"ooi260007r31","doi-asserted-by":"publisher","first-page":"6080","DOI":"10.1200\/JCO.2023.41.16_suppl.6080","article-title":"Neoadjuvant tislelizumab combined with APF for patients with locally advanced head and neck squamous cell carcinoma: a prospective single-arm clinical trial.","volume":"41","author":"Yan","year":"2023","journal-title":"J Clin Oncol"},{"key":"ooi260007r32","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2022.100177","article-title":"73P A randomized phase II study of neoadjuvant immunotherapy or immunochemotherapy in locally advanced oral squamous cell carcinoma.","volume":"16","author":"Chen","year":"2022","journal-title":"Immunooncol Technol"},{"issue":"1","key":"ooi260007r33","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13046-022-02510-2","article-title":"Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): an open label, single-arm, phase Ib clinical trial.","volume":"41","author":"Huang","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"ooi260007r34","doi-asserted-by":"publisher","first-page":"5378","DOI":"10.1038\/s41467-022-33080-8","article-title":"A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma.","volume":"13","author":"Ju","year":"2022","journal-title":"Nat Commun"},{"issue":"5","key":"ooi260007r35","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1158\/1078-0432.CCR-21-1816","article-title":"Tadalafil enhances immune signatures in response to neoadjuvant nivolumab in resectable head and neck squamous cell carcinoma.","volume":"28","author":"Luginbuhl","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"7","key":"ooi260007r36","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1158\/1078-0432.CCR-21-3351","article-title":"Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma.","volume":"28","author":"Wise-Draper","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"15","key":"ooi260007r37","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1158\/1078-0432.CCR-22-0666","article-title":"Neoadjuvant chemoimmunotherapy for the treatment of locally advanced head and neck squamous cell carcinoma: a single-arm phase 2 clinical trial.","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"ooi260007r38","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002568","article-title":"Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.","volume":"9","author":"Ferris","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"10","key":"ooi260007r39","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100426","article-title":"Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.","volume":"2","author":"Knochelmann","year":"2021","journal-title":"Cell Rep Med"},{"issue":"1","key":"ooi260007r40","doi-asserted-by":"publisher","first-page":"7348","DOI":"10.1038\/s41467-021-26472-9","article-title":"Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.","volume":"12","author":"Vos","year":"2021","journal-title":"Nat Commun"},{"issue":"10","key":"ooi260007r41","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/jamaoncol.2020.2955","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial.","volume":"6","author":"Schoenfeld","year":"2020","journal-title":"JAMA Oncol"},{"issue":"19","key":"ooi260007r42","doi-asserted-by":"publisher","first-page":"5140","DOI":"10.1158\/1078-0432.CCR-20-1695","article-title":"Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial.","volume":"26","author":"Uppaluri","year":"2020","journal-title":"Clin Cancer Res"},{"key":"ooi260007r43","doi-asserted-by":"publisher","first-page":"S682","DOI":"10.1016\/j.annonc.2020.08.1083","article-title":"Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) outcomes in HPV(-) resectable locally advanced head and neck cancer.","volume":"31","author":"Zinner","year":"2020","journal-title":"Ann Oncol"},{"key":"ooi260007r44","doi-asserted-by":"publisher","first-page":"S571","DOI":"10.1016\/j.annonc.2023.09.2040","article-title":"Neoadjuvant PD-1 inhibitor combined with Nab-paclitaxel and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NCT05522985): a randomized, controlled, open label, phase II clinical trial.","volume":"34","author":"Wang","year":"2023","journal-title":"Ann Oncol"},{"issue":"4","key":"ooi260007r45","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3390\/pharmaceutics13040520","article-title":"Advances in lipid-based nanoparticles for cancer chemoimmunotherapy.","volume":"13","author":"Wang","year":"2021","journal-title":"Pharmaceutics"},{"issue":"11","key":"ooi260007r46","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"ooi260007r47","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S1470-2045(20)30140-6","article-title":"Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.","volume":"21","author":"Shu","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"ooi260007r48","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1158\/2159-8290.CD-20-1312","article-title":"Paradigms on immunotherapy combinations with chemotherapy.","volume":"11","author":"Salas-Benito","year":"2021","journal-title":"Cancer Discov"},{"key":"ooi260007r49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1375136","article-title":"Comparative long-term outcomes of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy as first-line therapy for metastatic non-small-cell lung cancer: a systematic review and network meta-analysis.","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"issue":"15","key":"ooi260007r50","doi-asserted-by":"publisher","first-page":"3329","DOI":"10.1158\/1078-0432.CCR-24-0590","article-title":"Personalized ctDNA for monitoring disease status in head and neck squamous cell carcinoma.","volume":"30","author":"Hanna","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"ooi260007r51","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12885-024-11897-4","article-title":"Discontinuation risk from adverse events: immunotherapy alone vs. combined with chemotherapy: a systematic review and network meta-analysis.","volume":"24","author":"Shin","year":"2024","journal-title":"BMC Cancer"},{"issue":"33","key":"ooi260007r52","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1111\/1759-7714.15458","article-title":"Efficacy and safety of immunotherapy combined with chemotherapy in patients with ES-SCLC: a systematic review and network meta-analysis of RCTs and RWSs.","volume":"15","author":"Kang","year":"2024","journal-title":"Thorac Cancer"},{"issue":"11","key":"ooi260007r53","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S1470-2045(24)00498-4","article-title":"Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial.","volume":"25","author":"Provencio","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"ooi260007r54","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/JS9.0000000000000353","article-title":"Can adjuvant radiotherapy be omitted for oral cavity cancer patients who received neoadjuvant therapy and surgery: a retrospective cohort study.","volume":"109","author":"Ju","year":"2023","journal-title":"Int J Surg"},{"key":"ooi260007r55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1571285","article-title":"Oncologic outcomes following neoadjuvant immunochemotherapy in locally advanced oral squamous cell carcinoma.","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"issue":"5","key":"ooi260007r56","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.hoc.2021.05.003","article-title":"Lip and oral cavity squamous cell carcinoma.","volume":"35","author":"Howard","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"ooi260007r57","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1245\/s10434-024-16587-w","article-title":"Neoadjuvant immunotherapy in resectable HNSCC: an updated systematic review and meta-analysis.","volume":"32","author":"Widjaja","year":"2025","journal-title":"Ann Surg Oncol"}],"container-title":["JAMA Otolaryngology\u2013Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2845761\/jamaotolaryngology_baratz_2026_oi_260007_1778044141.68402.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:00:23Z","timestamp":1778770823000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2845761"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":57,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2026.0080","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,1]]}}}